

Cardiac involvement in hereditary myopathy with early respiratory failure

A cohort study

OPEN

Hannah E. Steele, MRCP
Elizabeth Harris, MRCP
Rita Barresi, PhD
Julie Marsh, MSc
Anna Beattie, FRCR
John P. Bourke, MD
Volker Straub, MD
Patrick F. Chinnery,
FRCP, FMedSci

Correspondence to
Dr. Chinnery:
pfc25@medschl.cam.ac.uk

ABSTRACT

Objective: To assess whether hereditary myopathy with early respiratory failure (HMERF) due to the c.951434T>C; (p.Cys31712Arg) *TTN* missense mutation also includes a cardiac phenotype.

Method: Clinical cohort study of our HMERF cohort using ECG, 2D echocardiogram, and cross-sectional cardiac imaging with MRI or CT.

Results: We studied 22 participants with the c.951434T>C; (p.Cys31712Arg) *TTN* missense mutation. Three were deceased. Cardiac conduction abnormalities were identified in 7/22 (32%): sustained atrioventricular tachycardia (n = 2), atrial fibrillation (n = 2), nonsustained atrial tachycardia (n = 1), premature supraventricular complexes (n = 1), and unexplained sinus bradycardia (n = 1). In addition, 4/22 (18%) had imaging evidence of otherwise unexplained cardiomyopathy. These findings are supported by histopathologic correlation suggestive of myocardial cytoskeletal remodeling.

Conclusions: Coexisting cardiac and skeletal muscle involvement is not uncommon in patients with HMERF arising due to the c.951434T>C; (p.Cys31712Arg) *TTN* mutation. All patients with pathogenic or putative pathogenic *TTN* mutations should be offered periodic cardiac surveillance.

Neurology® 2016;87:1031-1035

GLOSSARY

HMERF = hereditary myopathy with early respiratory failure; **LV** = left ventricular; **MFM** = myofibrillar myopathy; **NIV** = noninvasive ventilation; **RV** = right ventricular.

Hereditary myopathy with early respiratory failure (HMERF) is an autosomal dominant disorder arising due to missense mutations in the fibronectin III domain of the *TTN* gene, most commonly c.951434T>C; (p.Cys31712Arg).¹ HMERF is characterized by adult onset of distal or proximal muscle weakness in association with early respiratory muscle weakness, which may be the presenting feature and require noninvasive ventilation. Muscle biopsy findings are largely nonspecific, although myofibrillar myopathy and cytoplasmic bodies are described.²

Other skeletal myopathies caused by missense mutations in titin include tibial muscular dystrophy due to heterozygous mutations in the C-terminus³ and limb-girdle muscular dystrophy type 2J arising from recessive mutations at the same locus.⁴ Cardiac complications in these phenotypes have not been reported previously.^{1,3-5} Conversely, heterozygous truncating *TTN* mutations are a recognized cause of dilated⁶ and restrictive⁷ cardiomyopathies without apparent skeletal muscle involvement. However, the rare coexistence of skeletal and cardiac muscle disease in recessive truncating titin mutations⁶ raises the possibility that cardiac involvement may occur in other titinopathies. This has implications for the surveillance of those at risk. To address this, we carried out the first systematic cardiac study in HMERF using multimodal structural and functional cardiac imaging.

From the John Walton Muscular Dystrophy Research Centre (H.E.S., E.H., R.B., J.M., V.S.), Newcastle University; Department of Cardiology (A.B., J.P.B.), Freeman Hospital, NUTH NHS Foundation Trust; Medical Research Council Mitochondrial Biology Unit (P.F.C.); and Department of Clinical Neurosciences (P.F.C.), School of Clinical Medicine, University of Cambridge, UK.

Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by the Wellcome Trust.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Table 1 Clinical features of the UK hereditary myopathy with early respiratory failure cohort

Patient and family ID	Sex	Age at onset, y	DisD, y	Skeletal muscle pattern	Function	PFTs (% predicted)			Cardiac Hx, Ix, and Mx	12-Lead ECG	Echo summary	
						FEV ₁	FVC	NIV				
1	A	F	30	14	Distal LL	Unaided	72	71	N	No medication	Low-amplitude p waves	Segmental LV hypokinesis and ↓ LV EF 50%-55%
2	B	M	37	6	Distal > proximal LL > UL	AFO	52	68	N	Ramipril for high BP	Normal	Normal
3	B	M	33	13	Distal and proximal LL and distal UL	Unaided	83	85	Y	No medication	Normal	Grade 1 DD-NFA
4	B	F	40	10	Distal and proximal UL and LL and axial	Unaided	uk	53	N	Propranolol intermittently; 24-hour ECG = 11 beats AT	Tachycardic with premature atrial ectopics	E-E' 8-15, possible diastolic LV dysfunction
5	B	M	45	2	Mild distal UL and LL	Unaided	67	70	N	Palpitations; no meds; 24-hour ECG = normal	Normal	Normal
6	B	F	60	14	Mild distal LL weakness	Unaided	67	62	N	No medication	Bradycardic: 55 bpm	E-E' 8-15, possible diastolic LV dysfunction
7	B	M	16	32	Distal and proximal LL; distal UL	Stick	uk	73	N	No medication	Notched p waves	Poor view
8	B	F	29	14	Distal and proximal LL	Unaided	70	64	Y	AVNRT: ablation; no meds	Normal	Normal (LV EF low normal 55%)
9	B	M	35	30	Distal and proximal UL and LL	WC	33	32	Y	Lisinopril for high BP	Premature SV complexes	Grade 1 DD-NFA
10	B	M	44	15	Distal and proximal UL and LL	WC	67	63	Y	Palpitations; atorvastatin	Normal	Small LV cavity
11	B	M	20	34	Distal and proximal UL and LL	Crutch and AFO	57	55	N	2012: Perindopril 4 mg, bisoprolol 2.5 mg; 2014: perindopril 4 mg, bisoprolol 5 mg	Low-amplitude p waves, normal PR, flattened T waves (evolving over 2 years)	2012: LV EF 40%-45%; mild-moderate imp RV; 2013: LV EF 50%; 2014: LV EF >55%, low normal RV function, segmental CM; 2015: LV EF 50%
12	B	F	46	10	Distal and proximal LL; distal UL	WC	73	71	N	No medication	Premature atrial complexes	Normal
13	C	M	35	6	Distal and proximal LL; proximal UL	WC	uk	77	N	No medication	Low-amplitude notched p waves, nonspecific flattened T waves (evolving over 3 years)	2014: LV EF 50%; 2015: LV EF 55%
14	C	F	NA	NA	Nil	Unaided	uk	77	N	No medication	Normal	Normal
15	D	M	28	5	Distal and proximal UL and LL	AFO	uk	70	N	No medication	Normal	Normal
16	E	M	30	27	Distal LL and UL	uk	uk	68	N	No medication	uk	Normal
17	F	M	39	8	Distal LL and UL	uk	uk	uk	uk	No medication	Normal	Normal
18	G	M	27	15	Distal and proximal LL > distal UL	AFO	55	56	N	No medication	uk	Normal
19	H	M	30	33	Distal LL and UL	uk	uk	56	Y	SVT; bisoprolol	uk	uk
20*	I	M	45	4	Proximal and distal LL; proximal UL	Stick	67	71	N	No cardiac hx or medication	uk	uk
21*	J	M	uk	uk	Proximal and distal LL; mild proximal UL	uk	uk	uk	Y	PPM, AVR; uk medication	Atrial fibrillation	uk
22*	C	M	44	30	Distal > proximal LL > UL	WC	33	27	Y	2010: Bisoprolol 2.5 mg; furosemide 20-40 mg; 24-hour ECG: AF with variable rate	Atrial fibrillation	2007: LV EF 45%-50%; 2013: LV EF 50%

Abbreviations: AF = atrial fibrillation; AFO = ankle foot orthosis; AT = atrial tachycardia; AVNRT = atrioventricular nodal reentrant tachycardia; AVR = aortic valve replacement; BP = blood pressure; bpm = beats per minute; CM = cardiomyopathy; DD = diastolic dysfunction; DisD = disease duration; EF = ejection fraction; FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity; Hx = history; imp = impaired; Ix = investigations; LL = lower limb; LV = left ventricular; Mx = management; NA = not applicable; NFA = normal for age; NIV = noninvasive ventilation; PFTs = pulmonary function tests; PPM = permanent pacemaker; PR = PR interval; RV = right ventricular; SVT = supraventricular tachycardia; UL = upper limb; uk = unknown; WC = wheelchair; * = deceased patients.

METHODS All participants known to the John Walton Muscular Dystrophy Research Centre, Newcastle upon Tyne, United Kingdom, with the c.951434T>C; (p.Cys31712Arg) *TTN* missense mutation had a 12-lead ECG and echocardiogram requested as part of routine clinical care. All available cardiac test results were reviewed. Thereafter, all participants residing within the North East of England were invited to attend for a cardiac MRI, irrespective of cardiac symptomatology or initial findings. Where participants were unable to tolerate MRI, cardiac CT scan was offered.

All cardiac MRIs were performed on a 1.5T Siemens MRI scanner using a standardized cardiomyopathy protocol, with black blood anatomical, multiplanar short tau inversion recovery, multiplanar cines—including short axis stack for ventricular function, multiplanar cines, and delayed enhancement sequences obtained with gadoterate meglumine (Dotarem; Guerbet, Villepinte, France). All cardiac CT imaging was performed on a Siemens dual source CT scanner retrospectively gated at low dose for functional information only with a Flash mode delayed enhancement series 7 minutes following iohexol (Omnipaque; GE Healthcare, Cleveland, OH) administration.

Histopathologic correlation. Based on previous reports of desmin as a marker of cardiac dysfunction,⁸ we undertook analysis of frozen myocardial samples collected postmortem from 3 patients with HMERF.

Immunohistochemistry. Immunolabeling for β -spectrin (clone RBC2/3D5), desmin (DAKO M0760; Glostrup, Denmark), myotilin (NCL-Myotilin; Leica Biosystems, Newcastle, UK), VCP (BD Biosciences, East Rutherford, NJ), ubiquitin (NCL-UBIQm; Leica Biosystems), and p62 (Abcam ab56416; Cambridge, UK) was undertaken.


Western blot. Myocardial samples from patients and age-matched controls with no reported cardiac pathology were homogenized and run on sodium dodecyl sulfate polyacrylamide gel electrophoresis (4%–12% gradient). Immunoblotting was performed using the antibody against desmin. Immunoblots were visualized with SuperSignal West Pico Chemiluminescent Substrate detection using AlphaInnotech FluorChem Q platform and AlphaView software v3.0. All tests were performed in duplicate.

Standard protocol approvals, registrations, and patient consents. Clinical assessments were undertaken as routine clinical care. Consent and ethical approval was in place for the histopathologic studies.

RESULTS We identified 22 participants with the c.951434T>C; (p.Cys31712Arg) *TTN* mutation. Three were deceased. Eighteen attended for echocardiogram, of whom 6 subsequently had cardiac MRI and 4 cardiac CT imaging. Two individuals failed to attend planned MRI scans. Cross-sectional imaging was not requested in 7 patients due to geographic dispersion. Clinical features are outlined in table 1.

We identified conduction abnormalities in 32% (7/22) of patients. These included sustained atrioventricular tachycardia (8B and 19H), nonsustained atrial tachycardia (4B; figure, A), premature supraventricular complexes (9B), unexplained sinus bradycardia (6B), and atrial fibrillation (21J and 22C). Patients 8B and 19H were treated with bisoprolol and 8B underwent catheter ablation. Patients 5B and 10B had a history of

Figure Clinical and pathologic features of cardiac involvement in hereditary myopathy with early respiratory failure (HMERF)



(A) Twenty-four-hour ECG demonstrates nonsustained atrial tachycardia (patient 4B). (B) Cardiac MRI of 11B demonstrates subepicardial fibrosis (arrow). (C) Hematoxylin & eosin staining of myocardium in controls (C1 and C2) and patients with HMERF (20* and 21*). (D) Western blot staining for desmin (DES) and myosin heavy chain (MHC).

Table 2 Cardiac MRI and CT features

Patient and family	ID	Ix	RV: Ejection fraction, %	LV: Ejection fraction, %	Fibrosis?	Corrected end LV diastolic volume, mL/m ²	Corrected end RV diastolic volume, mL/m ²	Overall impression
1	A	MRI	44	60	N	51 (56-96)	63 (48-112)	(1) Subtle dyssynchronous ventricular contractions; (2) mild RV impairment
2	B	MRI	64	70	N	56 (57-105)	59 (61-121)	Normal
5	B	CT	57	60	N			Normal
6	B	CT	50	74	N			Subtly abnormal: mildly enlarged atria
7	B	MRI 2015	45	53	N	65 (57-105)	77 (61-121)	Normal (no cardiac medication)
		MRI 2012	38	45	N	90 (57-105)	109 (61-121)	Possible early cardiomyopathy: LVEF and LV volume in URN; no medication
8	B	MRI	56	57	N	70 (56-96)	69 (48-112)	Normal
9	B	CT		63	N			Normal
10	B	CT		72	N			Normal
11	B	MRI	41	60	Y	67 (57-105)	92 (55-105)	(1) Subepicardial fibrosis; (2) RV impairment without dilation of RV/PA
13	C	MRI	31	38	N	49 (47-92)	64 (61-121)	Mild nondilated, nonischemic cardiomyopathy

Abbreviations: Ix = investigations; LV = left ventricle; LVEF = left ventricular ejection fraction; PA = pulmonary artery; RV = right ventricle; URN = upper range of normal.

palpitations without specific diagnosis being reached despite investigation.

Asymptomatic global left ventricular systolic dysfunction was evident in 4/22 (18%) patients (1A, 11B, 13C, and 22*) on echocardiogram (tables 1 and 2). Although none had chamber dilation, the findings were compatible with nonischemic cardiomyopathy. Two were known to have reduced left ventricular (LV) ejection fraction at study onset (11B and 13C), and one was identified with mild right ventricular (RV) systolic dysfunction in the course of the study (1A). We identified subepicardial fibrosis in 11B on late gadolinium-enhanced MRI (figure, B). None had other lifestyle, history, or medical risk factors to explain their cardiac features.

Four individuals had evidence of possible or definite LV diastolic dysfunction by E-E' measures on echocardiography. Patient 9B was on maintenance lisinopril for hypertension, but none of the others (3B, 4B, 6B) had any history of cardiac disease, cardioactive medication use, or prior cardiology assessment. Patients 6B and 9B underwent cross-sectional cardiac imaging with CT and mild diastolic impairment was confirmed in 6B (tables 1 and 2).

Response to treatment. Participant 11B demonstrated sustained improvement in cardiac function in the 2012–2015 period following initiation of perindopril and bisoprolol therapy. Left ventricular function improved in patient 22* after commencing β -blocker therapy (table 1).

Relationship to disease onset. The age range of individuals developing cardiomyopathy overlapped with

those without (40–65 and 33–65 years, respectively) and with disease duration (6–34 and 2–33 years, respectively). Cardiomyopathy emerged 4–30 years after first skeletal muscle symptoms (table 1).

Relationship to respiratory disease. We assessed the relationship of confirmed ventricular systolic dysfunction at any time with respiratory disease and noninvasive ventilation (NIV) use. No relationship was identified between ventricular systolic impairment and respiratory disease (reduction in pulmonary function tests of 25% or more from predicted) or use of NIV ($p = 0.2722$ and $p = 0.2778$, respectively; Fisher exact test).

Histopathologic correlation. Immunohistochemistry. Myocardial tissue preservation was satisfactory in patient 20*, degraded in patient 21* (figure, C), and unsuitable for further analysis in patient 22*. Immunolabeling for myofibrillar proteins was unremarkable and did not demonstrate abnormal protein accumulation (not shown).

Immunoblot. Desmin expression was upregulated (approximately 2.5-fold) in patient 20* compared to controls, suggesting myocardial cytoskeletal remodeling.⁸ Patient 21* showed reduced desmin expression consistent with extensive postmortem delay (figure, D).

DISCUSSION Our findings show that cardiac involvement is not uncommon in patients with the c.951434T>C (p.Cys31712Arg) *TTN* missense mutation. Conduction abnormalities occurred in a third of patients, with atrial fibrillation and sustained paroxysmal atrioventricular tachycardia most frequently identified (2/22; 9% each). The prevalence of the latter arrhythmia

is significantly higher than seen in the general population (9% vs 0.2%; $p = 0.0026$; Fisher exact test).⁹

Additionally, cardiomyopathy was identified in 18% (4/22). Importantly, this was responsive to standard cardioactive therapies. Interestingly, the presence of either LV or RV dysfunction was independent of respiratory failure, suggesting the mechanism is not secondary to nocturnal hypoventilation, restrictive pulmonary physiology, or cor pulmonale. The etiology of the diastolic dysfunction observed is uncertain given the absence of LV hypertrophy or significant fibrosis. Diastolic dysfunction is a recognized feature of cardiovascular aging and consequently, is the most likely explanation for our findings. However, a disease-specific association cannot be excluded.

As a recently recognized cause of myofibrillar myopathy (MFM), the *TTN* mutation causing HMERF is now included in genetic testing panels for MFM.² Cardiac involvement in other myofibrillar myopathies, also encompassing arrhythmia and cardiomyopathy, is well-recognized, with an estimated prevalence of 30%.¹⁰ Our findings are in keeping with this.

The main limitation of our study is its pragmatic nature as it was conducted in the context of routine clinical health care. Consequently, the echocardiograms were performed and reported by several—albeit experienced—echo-technicians and the CT scans were reported retrospectively. While MRI remains the gold standard investigation for assessment of ventricular function, use of CT in this population, with neuromuscular respiratory failure and NIV, enabled more patients to undergo cross-sectional cardiac imaging. Although the 2 modalities are not directly comparable, where imaging is undertaken longitudinally using the same method, an assessment of change can be made.

As the full spectrum of cardiac and skeletal muscle phenotypes associated with *TTN* mutations remains unknown, patients with pathogenic or putative pathogenic *TTN* mutations should be offered periodic cardiac surveillance. However, based on the findings we present here, some of the observed abnormalities may be due to normal aging, and not *TTN* cardiomyopathy per se.

AUTHOR CONTRIBUTIONS

Dr. Steele: wrote the first draft manuscript, study coordination, acquisition of data, interpretation of data. Dr. Harris: drafting manuscript, study coordination, acquisition of data, interpretation of data. Dr. Barresi: revising manuscript for content, acquisition of data, analysis of data, interpretation of data. J. Marsh: acquisition of data. Dr. Beattie: revising manuscript for content, interpretation of data. Dr. Bourke: revising manuscript for content, interpretation of data. Prof. Straub: study concept and design, acquisition of data, study supervision, revising manuscript for content. Prof. Chinnery: study concept and design, acquisition of data, analysis, interpretation, study supervision, wrote the first draft manuscript.

ACKNOWLEDGMENT

The authors thank the patients, cardiac technicians, and radiographers for their assistance in screening patients. Direct sequencing of the common HMERF missense mutation c.951434T>C; (p.Cys31712Arg) was performed by the Northern Genetics Service. Mutations are reported using the reference sequence NM_001267550.1.

STUDY FUNDING

P.F.C. is a Wellcome Trust Senior Fellow in Clinical Science (101876/Z/13/Z) and a UK NIHR Senior Investigator who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UP_1501/2), the Wellcome Trust Centre for Mitochondrial Research (096919Z/11/Z), the Medical Research Council (UK) Centre for Translational Muscle Disease research (G0601943), EU FP7 TIRCON, and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

DISCLOSURE

The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Received January 25, 2016. Accepted in final form May 26, 2016.

REFERENCES

1. Pfeffer G, Elliott HR, Griffin H, et al. Titin mutation segregates with hereditary myopathy with early respiratory failure. *Brain* 2012;135:1695–1713.
2. Pfeffer G, Barresi R, Wilson IJ, et al. Titin founder mutation is a common cause of myofibrillar myopathy with early respiratory failure. *J Neurol Neurosurg Psychiatry* 2014;85:331–338.
3. Hackman P, Vihola A, Haravuori H, et al. Tibial muscular dystrophy is a titinopathy caused by mutations in *TTN*, the gene encoding the giant skeletal-muscle protein titin. *Am J Hum Genet* 2002;71:492–500.
4. Haravuori H, Makela-Bengs P, Udd B, et al. Assignment of the tibial muscular dystrophy locus to chromosome 2q31. *Am J Hum Genet* 1998;62:620–626.
5. Udd B, Partanen J, Halonen P, et al. Tibial muscular dystrophy: late adult-onset distal myopathy in 66 Finnish patients. *Arch Neurol* 1993;50:604–608.
6. Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. *N Engl J Med* 2012;366:619–628.
7. Peled Y, Gramlich M, Yoskovitz G, et al. Titin mutation in familial restrictive cardiomyopathy. *Int J Cardiol* 2014;171:24–30.
8. Monreal G, Nicholson LM, Han B, et al. Cytoskeletal remodeling of desmin is a more accurate measure of cardiac dysfunction than fibrosis or myocyte hypertrophy. *Life Sci* 2008;83:786–794.
9. Orejarena LA, Vidaillet H, DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population. *J Am Coll Cardiol* 1998;31:150–157.
10. Semmler AL, Sacconi S, Bach JE, et al. Unusual multisystemic involvement and a novel BAG3 mutation revealed by NGS screening in a large cohort of myofibrillar myopathies. *Orphanet J Rare Dis* 2014;9:121.

Neurology[®]

Cardiac involvement in hereditary myopathy with early respiratory failure: A cohort study

Hannah E. Steele, Elizabeth Harris, Rita Barresi, et al.

Neurology 2016;87:1031-1035 Published Online before print August 10, 2016

DOI 10.1212/WNL.0000000000003064

This information is current as of August 10, 2016

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/87/10/1031.full
References	This article cites 10 articles, 2 of which you can access for free at: http://n.neurology.org/content/87/10/1031.full#ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Genetics http://n.neurology.org/cgi/collection/all_genetics All Neuromuscular Disease http://n.neurology.org/cgi/collection/all_neuromuscular_disease CT http://n.neurology.org/cgi/collection/ct MRI http://n.neurology.org/cgi/collection/mri Muscle disease http://n.neurology.org/cgi/collection/muscle_disease
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2016 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

